NEWS
RCPath chooses Dr Bernie Croal as President Elect
Dr Bernie Croal has been elected by the College membership as President Elect of The Royal College of Pathologists. Dr Bernie Croal is an NHS chemical pathologist from Aberdeen specialising in intravenous nutritional support. He also oversees laboratory services at the Cleveland Clinic in London via TDL. He is a science and medicine graduate, and has trained in general medicine, chemical pathology and Health Services/
Public Health Research. He has spent a long career in various leadership roles within NHS Scotland including clinical director and regional lead for pathology, NHS Scotland demand optimisation lead and chair of the Scottish Clinical Biochemistry Network (SCBN). He is the current (2021–2023)
President of the Association for Clinical Biochemistry and Laboratory Medicine (ACB-UK). He is a fellow of both the Royal College of Physicians and Surgeons of Glasgow and the Institute of Biomedical Science. Within RCPath he has chaired many committees, been Scotland Regional Council Chair for nine years and a Trustee for 13 years. He served as College Vice President from 2011 to 2014. Professor Mike Osborn, President, The Royal College of Pathologists said: “I am delighted to announce that Dr Bernie Croal has been appointed as President Elect of The Royal College of Pathologists. Bernie will bring a wealth of insight to the role, both from his extensive clinical experience as well from his time serving as a College Trustee working in a number of roles, most recently as Chair of RCPath Scotland Regional Council. Dr Bernie Croal added: “I am delighted and honoured to be elected as President of the Royal College of Pathologists. Pathology is more important than ever, and as President, I will work to ensure that the work of the College continues to be vital and relevant to members and most importantly to patients.”
12
UK health research at risk says Academy of Medical Sciences
Action must be taken now to stop the UK from losing its exceptional strengths in health research, and the value it brings to society, says a new report published by the Academy of Medical Sciences. The report, entitled: ‘Future-proofing UK Health Research: a people-centred, coordinated approach’, details key threats to UK health research and the steps needed to protect it. Health research saves and
improves lives, for example by producing world-renowned breakthroughs such as sequencing the human genome and developing life-saving vaccines. It also drives the economy; every £1 of public investment in medical research delivers a return equivalent to around 25p each year, forever. To secure a sustainable future for
research and deliver maximum health benefits for people everywhere, the report calls for coordinated action. This involves
governments across the UK, public and charitable funders, higher education institutions, industry, NHS leaders, patients, carers, and the public. It concludes that UK health research is in danger of being taken for granted and sets out what needs to be done to improve and future-proof it. The report was produced by 30 experts from across the UK, including established and emerging research leaders, patients, carers
and representatives from the public, private and charitable sectors. Chaired by Professor Dame Julia Goodfellow FMedSci and Professor Sir Peter Mathieson FRSE FMedSci, the group analysed the strengths in the health research system and identified factors which threaten the UK’s ability to deliver health and economic benefits in the long term.
Read the full report at https://acmedsci.
ac.uk/file-download/23875189
Roche looks to advance human model systems
Roche has announced the launch of the Institute of Human Biology (IHB) focusing on advancing research in the field of human model systems such as organoids.
Leveraging human model systems, the institute aims to accelerate drug discovery and development by improving the understanding of how organs function and how diseases develop, ultimately bringing medicines to patients faster. Human model systems are miniature 2D or 3D living ‘replicas’ of human tissues and organs that scientists create from human stem cells. By mirroring human and disease biology more accurately than animal models, they can also help reduce the reliance on animal testing. In addition, human model systems may enable the discovery of new human biology (in health and disease) and identification of drug targets that are impossible to find with classical discovery approaches. Pictured are engineered mammary
glands on a chip. Through the use of these bioengineered tissues, IHB researchers can study mammary gland morphogenesis, milk secretion and branching in vitro. “Human model systems such as
organoids are the future of our industry. They have the potential to enhance almost all the steps involved in the research and development of an innovative medicine”, says Professor Dr Hans Clevers, Head of Pharma Research and Early Development (pRED) at Roche and a pioneer in the field of organoids. “The IHB will address urgent challenges in drug discovery and development with the ambition to bring medicines to patients faster.” To learn more about the Institute of Human Biology visit the website at
institutehumanbiology.com.
JUNE 2023
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
